Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Emotional Regulation, Virtual Reality, A...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Introduction and Significance: Preventive interventions have been shown to reduce the risk of developing anxiety and depression, making them a critical focus area in mental health promotion for children and adolescents. Enhancing emotion regulation (ER) skills in young people is one approach to preventing anxiety and depression, as ER involves cognitive processes of modifying thoughts and behaviors to manage emotional responses in different contexts. Executive functions (EF), such as cognitive flexibility, working memory, and inhibition, play a crucial role in ER development and regulation in children and adolescents. Recently, immersive virtual reality (IVR) has emerged as a novel tool for improving cognitive training interventions' accessibility and effectiveness. IVR allows users to experience immersive, three-dimensional environments, where they can interact with objects and events in a highly engaging and realistic way. Considering these developments, this study aims to explore the potential benefits of Enhance VR, a gamified IVR program designed to improve ER skills and reduce anxiety and depressive symptoms among children and adolescents. Methodology: The study will be a longitudinal, parallel, single-blind, randomized controlled pilot trial involving 80 Spanish - or English-speaking participants aged 10 to 16 years old. Participants will be excluded if they have severe psychiatric or neurodevelopmental disorders, physical, motor, or sensory impairments, or a risk of experiencing high cybersickness symptomatology during the VR experience. Participants will be randomly allocated into two groups: an experimental group receiving E-Emotio VR and a control group receiving a placebo-based VR relaxation experience. Both VR interventions will last five weeks, two times a week, for 30 minutes. The experimental group will engage in six games targeting cognitive flexibility, planning, reappraisal strategies, working memory, divided and sustained attention, and processing speed. The control group will be immersed in ten different nature-based VR environments and perform relaxation exercises. Baseline and post-intervention assessments will be conducted using age-adapted validated measures of depressive and anxiety symptoms, ER, executive function (working memory, cognitive flexibility, inhibition, and planning), and attention. Following the intervention, the assessment battery will be re-administered by a blinded assessor, and statistical analyses will be conducted for all the primary and secondary measures assessed before and after the intervention in both groups. Conclusion: In summary, this study aims to contribute to the development of effective preventive interventions for emotion regulation and mental health symptoms in children and adolescents by promoting ER through gamified VR cognitive training. The study's findings could have significant implications for mental health research, educational and clinical practice. By exploring the potential…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: VR cognitive training — The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.
  • Behavioral: VR nature exposure relaxation — The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).

Primary Outcomes

  • Emotion Regulation Questionnaire for Children and Adolescents (ERQ-CA) (At baseline and after 5 weeks.)
  • Revised Child Anxiety and Depression Scale (RCADS-47) (At baseline)
  • State-Trait Anxiety Inventory for Children (STAI-C) (At baseline and after 5 weeks.)
  • Children's Depression Inventory (CDI) (At baseline and after 5 weeks.)
  • Positive and Negative Affect Schedule (PANAS) (At baseline and after 5 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-01
Completion: 2026-04-25
Eligibility
Age: 10 Years – 16 Years
Sex: ALL
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitat Internacional de Catalunya
Contact Information
Study Contact:
Bruno O Porras Garcia, PhD
(+34) 935 042 000
bporras@uic.es
Bruno O Porras Garcia
UIC Barcelona International University of Catalonia
Interventions
  • Behavioral: VR cognitive training — The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.
  • Behavioral: VR nature exposure relaxation — The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).
Study Locations (1 sites)
UIC Barcelona International University of Catalonia, Barcelona, Spain
Eligibility Criteria
Inclusion Criteria: * School-aged participants (aged 10 to 16 years old) * Individuals who provide consent to participate. Exclusion Criteria: * A previous diagnosis of severe psychiatric (e.g., maniac, or psychotic symptoms). * A previous diagnosis of severe psychiatric neurodevelopmental disorders (i.e., severe autism spectrum disorders, intellectual disabilities, etc), * A previous diagnosis of severe physical, motor, or sensory impairments that could interfere with the examination or the VR program. * Participants who cannot understand Spanish.
Conditions Major Depression
Phase NA
Enrollment 150
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this psychotherapy clinical trial is to evaluate whether a algorithm-based personalized modular psychotherapy is more effective than usual individual psychotherapy in treating major depressive disorder complicated by personality dysfunction and/or complex trauma in adults aged 18 to 65 receiving care in the Chilean public mental health system. The main questions it aims to answer are: * Does algorithm-based modular psychotherapy lead to greater clinically significant reduction and remission of depressive symptoms compared to usual psychotherapy? * Does algorithm-based modular psychotherapy lead to greater improvement in emotional regulation, interpersonal functioning, and self-related functioning, including changes observed in daily life? Researchers will compare algorithm-based modular psychotherapy to usual individual psychotherapy provided in public community mental health centers to see if the modular, personalized approach results in better clinical outcomes, stronger therapeutic alliance, and higher treatment satisfaction. Participants will: * Be randomly assigned to receive either algorithm-based modular psychotherapy or usual individual psychotherapy * Attend weekly individual psychotherapy sessions * Complete structured diagnostic interviews and self-report questionnaires before, during, and after treatment * Provide brief daily reports on mood, emotions, and interpersonal experiences using a smartphone before and after treatment

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Modular Intervention for Depression Therapy (MIND Therapy) — The MIND intervention is an algorithm-based, personalized, modular psychotherapy for adults with depression complicated by personality dysfunction and/or complex trauma. All participants receive a core evidence-based depression treatment that includes behavioral activation, cognitive, and interpersonal psychotherapy strategies. Additional short therapy modules are selected based on each participant's baseline emotional, interpersonal, and self-related functioning profile, using a predefined clinical algorithm. These modules target specific difficulties such as emotion regulation problems (DBT Module), sensitivity to rejection and interpersonal threat (MBT and CBASP Modules), social functioning difficulties (Social Thinning Module). The type and number of modules are tailored to individual needs following an algorithm based on baseline measures (DERS, A-RSQ, OQ-45-IR). Treatment is delivered as weekly individual psychotherapy sessions.
  • Behavioral: Psychotherapy as Usual (TAU) — Psychotherapy as usual (TAU) consists of individual psychotherapy delivered in public community mental health centers according to routine clinical practice. Treatment is provided weekly by trained clinicians and may vary in therapeutic orientation, techniques, and structure depending on the therapist and center. TAU is not guided by the modular psychotherapy protocol or algorithm used in the experimental intervention and reflects standard care available in the Chilean public mental health system.

Primary Outcomes

  • Depression remission. (Baseline (pre-intervention), end of treatment (session 15; approximately 3 months), and 3-month post-treatment (approximately 6 months after baseline assessment).)
  • Clinically significant symptom reduction (Baseline (pre-intervention), end of treatment (session 15; approximately 3 months), and 3-month post-treatment (approximately 6 months after baseline assessment).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-01
Completion: 2028-02-28
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pontificia Universidad Catolica de Chile
Collaborators: MIDAP Millennium Institute for Research in Depression and Personality
Contact Information
Study Contact:
Alex J Behn, PhD
+56942152484
albehn@uc.cl
Jorge Matamala, Bachelor of Psychology
+56982504691
jmatamale@uc.cl
Director
+56925762330
matiascorrearamirez@gmail.com
CDT CASR
Interventions
  • Behavioral: Modular Intervention for Depression Therapy (MIND Therapy) — The MIND intervention is an algorithm-based, personalized, modular psychotherapy for adults with depression complicated by personality dysfunction and/or complex trauma. All participants receive a core evidence-based depression treatment that includes behavioral activation, cognitive, and interpersonal psychotherapy strategies. Additional short therapy modules are selected based on each participant's baseline emotional, interpersonal, and self-related functioning profile, using a predefined clinical algorithm. These modules target specific difficulties such as emotion regulation problems (DBT Module), sensitivity to rejection and interpersonal threat (MBT and CBASP Modules), social functioning difficulties (Social Thinning Module). The type and number of modules are tailored to individual needs following an algorithm based on baseline measures (DERS, A-RSQ, OQ-45-IR). Treatment is delivered as weekly individual psychotherapy sessions.
  • Behavioral: Psychotherapy as Usual (TAU) — Psychotherapy as usual (TAU) consists of individual psychotherapy delivered in public community mental health centers according to routine clinical practice. Treatment is provided weekly by trained clinicians and may vary in therapeutic orientation, techniques, and structure depending on the therapist and center. TAU is not guided by the modular psychotherapy protocol or algorithm used in the experimental intervention and reflects standard care available in the Chilean public mental health system.
Study Locations (5 sites)
CDT CASR, Santiago, Chile
COSAM La Bandera, Santiago, Chile
COSAM La Granja, Santiago, Chile
COSAM La Pintana, Santiago, Chile
COSAM Rinconada, Santiago, Chile
Eligibility Criteria
Inclusion Criteria: * Current diagnosis of major depressive disorder, defined as: * Positive diagnosis on the MINI diagnostic interview, and * PHQ-9 score greater than 10 * Evidence of personality dysfunction, defined as a score above the cutoff on the Level of Personality Functioning Scale-Brief Form (LPFS-BF 2.0). * History of moderate to severe early life adversity, defined as elevated scores on at least one scale of the Childhood Trauma Questionnaire (CTQ), and/or clinically significant alterations in self-organization. * Presence of at least one elevated domain of alteration of self-organization, including emotion regulation difficulties, interpersonal sensitivity, and/or interpersonal functioning problems, as assessed by standardized self-report measures (DERS, A-RSQ, OQ-45-IR). * Receiving care at a participating public community mental health center in Chile. * Ownership of a smartphone (Android or iOS) with internet access and an active data plan. * Ability to provide written informed consent. Exclusion Criteria: * Acute suicide risk requiring immediate intensive intervention, as assessed by the MINI. * Any severe psychiatric disorder other than major depressive disorder that is the primary clinical diagnosis, including: * Schizophrenia or other psychotic disorders * Bipolar I disorder * Severe substance use disorder, active within the past 6 months. * Diagnosis of post-traumatic stress disorder (PTSD) meeting full diagnostic criteria, as assessed by standardized instruments (ITEM and ITQ). * Meeting diagnostic criteria for: * Antisocial personality disorder (two or more criteria), or * Borderline personality disorder with more than three diagnostic criteria * Severe medical, cognitive, or psychosocial condition that would interfere with participation in weekly psychotherapy. * Concurrent participation in another active psychotherapy or initiation/change of psychotropic medication during the study period, except for: * Stable antidepressant treatment * Medications prescribed for sleep * Benzodiazepines used only on an as-needed (PRN) basis. * Inability to comply with study procedures or assessments.
Conditions Major Depressive Disorder, Substance Use...
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Low-income individuals have limited access to evidence-based interventions for mental health. Peer recovery specialists, individuals in recovery from mental health and/or substance use problems, have the potential to increase access to evidence-based interventions for individuals from low-resource communities, particularly when trained and supervised in models that are acceptable and feasible in these communities. This study will examine the effectiveness and implementation potential of a peer-delivered evidence-based intervention (Behavioral Activation) among individuals receiving services from a community-based treatment setting providing integrated physical and behavioral healthcare.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Peer Activate — Peer Activate is an adapted behavioral activation (BA) intervention, developed for delivery by peer recovery specialists to reduce rates of depressive symptoms and substance use. BA focuses on increasing positive reinforcement through engaging in adaptive, valued behaviors. BA has been found to be effective in improving substance use outcomes and decreasing depressive symptoms among low-income individuals with SUD. Peer Activate includes 6 weekly sessions with up to 6 additional booster sessions.
  • Behavioral: Peer-delivered non-specific services — Peers will deliver non-specific peer services, including linkage to care, general support, and facilitated referrals to external providers as needed.

Primary Outcomes

  • Change in Hamilton Depression Rating Scale (Baseline, post-intervention (approximately 3 months after baseline), 6- and 12-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-01
Completion: 2029-01-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wayne State University
Collaborators: University of Maryland, College Park, Detroit Recovery Project INC
Contact Information
Study Contact:
Julia Felton, PhD
7049957832
hv8914@wayne.edu
Andre Johnson, PhD
Detroit Recovery Project
Interventions
  • Behavioral: Peer Activate — Peer Activate is an adapted behavioral activation (BA) intervention, developed for delivery by peer recovery specialists to reduce rates of depressive symptoms and substance use. BA focuses on increasing positive reinforcement through engaging in adaptive, valued behaviors. BA has been found to be effective in improving substance use outcomes and decreasing depressive symptoms among low-income individuals with SUD. Peer Activate includes 6 weekly sessions with up to 6 additional booster sessions.
  • Behavioral: Peer-delivered non-specific services — Peers will deliver non-specific peer services, including linkage to care, general support, and facilitated referrals to external providers as needed.
Study Locations (1 sites)
Detroit Recovery Project, Detroit, Michigan 48208 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 years old or older * Report clinically-significant symptoms of depression, as indexed by a score of 8+ on the PHQ-9. Exclusion Criteria: * Active, under treated psychotic symptoms or mania that would interfere with participation in study procedures * Inability to provide informed consent and/or complete procedures in English
Conditions Major Depressive Disorder, Bipolar Disor...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, open-label clinical trial aims to compare a novel "Venous Tourniquet with Regional Low-Dose Sugammadex" method against the gold standard "Arterial Tourniquet" (Isolated Forearm Technique - IFT) for monitoring motor seizure activity during Electroconvulsive Therapy (ECT). Using a within-subject (intra-individual) design, each of the 40 enrolled patients will receive an arterial tourniquet on one arm and a venous tourniquet on the other arm simultaneously. The study will evaluate clinical efficacy in observing motor seizures, comparing the duration and visibility between the two limbs of the same patient, as well as assessing overall patient comfort and hemodynamics.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Device: Arterial Tourniquet — Within the same patient, the arm without intravenous access is fitted with an arterial tourniquet (\>250 mmHg or 100 mmHg above systolic BP) before the systemic administration of 0.6 mg/kg rocuronium.
  • Device: Device: Venous Tourniquet — Within the same patient, the arm with intravenous access receives a venous tourniquet (elastic or 70 mmHg) after systemic rocuronium administration, followed by a regional IV injection of 0.3 mg/kg sugammadex (diluted in 20 ml saline) into that specific limb.
  • Drug: Sugammadex — Regional IV injection of 0.3 mg/kg sugammadex into the experimental limb.

Primary Outcomes

  • Motor Seizure Duration (From the initiation of the ECT electrical stimulus until the complete cessation of visible motor seizure activity in the limbs, assessed up to a maximum of 5 minutes.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-20
Completion: 2026-12-20
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medipol University
Contact Information
Study Contact:
Burak Ömür
+905056215056
bomur@medipol.edu.tr
Istanbul Medipol University
Interventions
  • Device: Device: Arterial Tourniquet — Within the same patient, the arm without intravenous access is fitted with an arterial tourniquet (\>250 mmHg or 100 mmHg above systolic BP) before the systemic administration of 0.6 mg/kg rocuronium.
  • Device: Device: Venous Tourniquet — Within the same patient, the arm with intravenous access receives a venous tourniquet (elastic or 70 mmHg) after systemic rocuronium administration, followed by a regional IV injection of 0.3 mg/kg sugammadex (diluted in 20 ml saline) into that specific limb.
  • Drug: Sugammadex — Regional IV injection of 0.3 mg/kg sugammadex into the experimental limb.
Study Locations (1 sites)
Istanbul Medipol University, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Patients scheduled for elective Electroconvulsive Therapy (ECT). * ASA (American Society of Anesthesiologists) physical status I to III. Exclusion Criteria: * Known neuromuscular diseases (e.g., Myasthenia Gravis). * Known allergy or hypersensitivity to sugammadex, rocuronium, ketamine, dexmedetomidine, or propofol. * Presence of venous insufficiency, lymphedema, or active infection in the upper extremities. * Severe cardiovascular instability.
Conditions Major Depressive Disorder, Depression in...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-site open-label clinical trial of fMRI-guided accelerated intermittent theta burst stimulation. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS)-is effective as a first-line therapy in treating adolescents aged 13-20 years-old in their first episode of depression who have not undergone a full course of depression treatment prior to starting the trial and who remain antidepressant-free throughout the trial. The main questions this trial aims to answer are: * Does aiTBS relieve symptoms of depression as a first-line therapy in adolescents? * Is aiTBS a feasible option as a first-line treatment for adolescent depression? Researchers will measure the depression symptoms in adolescent participants before and after aiTBS. Parents of the adolescent participant will also participate in the study providing information about their experience and preference for TMS as a first-line treatment. Adolescent participants will: * Remain antidepressant-free throughout the study period of 6-7 weeks. * Receive an fMRI of their head for precision targeting * Receive 5 days of aiTBS

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: MagPro X100 edition (MagVenture, Skovlunde, Denmark) — 10 daily sessions (50 total over 5-days) of aiTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
  • Device: MagPro X100 edition (MagVenture, Skovlunde, Denmark) — 5 daily sessions (25 total over 5-days) of aiTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).

Primary Outcomes

  • Childhood Depression Rating Scale-Revised (CDRS-R) Remission Rates (Baseline, One Month Follow Up Visit)
  • Childhood Depression Rating Scale-Revised (CDRS-R) Remission Rates (Baseline, One Month Follow Up Visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2027-12
Eligibility
Age: 13 Years – 20 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas at Austin
Collaborators: Magnus Medical
Principal Investigators:
  • Sean J O'Sullivan, M.D., Ph. D. (PRINCIPAL_INVESTIGATOR) - University of Texas at Austin
Contact Information
Study Contact:
Daniella Santos
512-495-5566
daniella.santos@austin.utexas.edu
Elyse Lemke
512-495-5566
elyse.lemke@austin.utexas.edu
Dell Medical School at University of Texas at Austin
Psychclinicaltrials@austin.utexas.edu
Dell Medical School at University of Texas at Austin
Interventions
  • Device: MagPro X100 edition (MagVenture, Skovlunde, Denmark) — 10 daily sessions (50 total over 5-days) of aiTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
  • Device: MagPro X100 edition (MagVenture, Skovlunde, Denmark) — 5 daily sessions (25 total over 5-days) of aiTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
Study Locations (1 sites)
Dell Medical School at University of Texas at Austin, Austin, Texas 78731 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or Female, between the ages of 13 and 20 at the time of screening. 2. Able to read, understand, and provide written, dated assent and/or consent prior to screening. Proficiency in English sufficient to complete questionnaires and follow instructions during aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information. 3. Diagnosed with Major Depressive Disorder (MDD) with a current Major Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5). 4. No prior major depressive episodes (MDEs) as determined by MINI-KID 5. CDRS-R score of ≥40 at screening (Visit 1). 6. Treatment-naive as determined by the ATHF (no adequate antidepressant trials prior to screening defined as fewer than 12 weeks of antidepressant medication in the past 2 years and fewer than 10 psychotherapy sessions for depression in the past year; willingness to taper medications and stop psychotherapy if recently started and within the window defined above.) 7. TMS naive. 8. Access to ongoing psychiatric care before and after completion of the study. 9. In good general health, as evidenced by medical history. 10. Agreement to adhere to Lifestyle Considerations throughout study duration. Exclusion Criteria: 1. Pregnancy 2. High-risk for suicide or active suicidal ideation as determined by clinical interview 3. The presence or diagnosis of prominent anxiety disorder, or dysthymia (\>4 on SAPAS; \>16 on GAD-7) 4. Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation) 5. Current mania or psychosis 6. Bipolar Affective Disorder and/or primary psychotic disorders. 7. Autism Spectrum disorder or Intellectual Disability 8. A diagnosis of obsessive-compulsive disorder (OCD) 9. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal. 10. Urine screening test positive for illicit substances. 11. Any history of ECT (greater than 8 sessions) without meeting responder criteria 12. Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT). 13. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma. 14. Untreated or insufficiently treated endocrine disorder. 15. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion) 16. Contraindications to MRI (ferromagnetic metal in their body). 17. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation. 18. Depth-adjusted aiTBS treatment dose \> 65% maximum stimulator output (MSO) 19. Treatment with another investigational drug or other intervention within the study period. 20. Any other condition deemed by the PI to interfere with the study or increase risk to the participant.
Conditions Hypertension, Obstructive Sleep Apnea
Phase Not Applicable
Enrollment 633
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Study name: Screening, Diagnosis and Treatment of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China: A Prospective National Multi-center Registry. Rationale: Obstructive sleep apnoea syndrome (OSAS) is a common secondary cause of hypertension and significantly correlated with the risk of cardiovascular and cerebrovascular diseases. However, continuous positive airway pressure (CPAP) only shows modest blood pressure lowering effect, although it is effective in the relieve of daytime sleepiness and other symptoms of OSAS. One of the possible reasons for the low antihypertensive efficacy might be the low adherence to CPAP therapy. Nonetheless, few studies systematically investigated CPAP adherence with regard to its prediction and clinical relevance for cardiovascular protection and prevention. Objective: 1) To evaluate short- and long-term CPAP adherence in patients with hypertension and obstructive sleep apnea syndrome; 2) To investigate the predictors of short- and long-term CPAP adherence; 3) To explore the correlation between the CPAP adherence and blood pressure, target organ damage and the incidence of cardiovascular and cerebrovascular events. Study design: Prospective, multi-center, observational study. Study population: Patients with hypertension who are suspected to have obstructive sleep apnea syndrome due to snoring, daytime sleepiness and other related symptoms are considered eligible and should meet the following criterias: 1) Agree to participate in the study and sign the informed consent; 2) At least 18 years old; 3) STOP-Bang questionnaire, score ≥3 points; 4) Complete polysomnography in hospital; 5) Currently on CPAP therapy. Follow up: 3, 6 and 12 months after registry. Sample size estimation: At least 633 patients. Timeline: Start of subjects' enrollment: Jan 2023; End of subjects' enrollment: December 2026; End of study: December 2026. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Continuous positive airway pressure — Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.

Primary Outcomes

  • Change in mean 24-hour ambulatory blood pressure after 12-month CPAP treatment from baseline (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 633 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Jiao Tong University School of Medicine
Principal Investigators:
  • Jiguang Wang, MD, PhD (PRINCIPAL_INVESTIGATOR) - Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Contact Information
Study Contact:
Jiguang Wang, MD, PhD
+86-21-64370045
jiguangw@163.com
Jiguang Wang, MD, PhD
+86-21-64370045
iguang_wang_jgw@yahoo.com
Jiguang Wang, MD, PhD
+86-21-64370045
jiguangw@163.com
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Interventions
  • Device: Continuous positive airway pressure — Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.
Study Locations (1 sites)
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality 200025 China
Eligibility Criteria
Inclusion Criteria: 1. Agree to participate in the study and sign the informed consent; 2. At least 18 years old; 3. STOP-Bang questionnaire, score ≥3 points; 4. Complete polysomnography in hospital; 5. Currently on CPAP therapy. Exclusion Criteria: 1. Clinic systolic/diastolic blood pressure ≥180/110 mmHg; 2. Previous or current treatment for OSAS without CPAP; 3. Severe respiratory diseases such as chronic obstructive pulmonary disease, or contraindications to CPAP therapy, such as pneumothorax, pulmonary bulla and new-onset stroke; 4. Sleep disorders or insomnia; 5. Intolerance of CPAP therapy; 6. Patient with cognitive dysfunction who are unable to provide informed consent; 7. Other circumstances that patients are not appropriate for the study upon the investigator's judgment.
Conditions Glaucoma
Phase PHASE4
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Brimonidine Tartrate Ophthalmic 0.025% — Lumify is an approved eye drop to minimize ocular hyperemia.

Primary Outcomes

  • Effron Grading scale of ocular redness (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-11-01
Completion: 2027-06-01
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Contact Information
Study Contact:
Crystal Remington Optometrist, OD
816-531-9100
drremington@vseyecare.com
Megan Hefter Research Coordinator
816-531-9100
mh@vseyecare.com
Vision Source
Interventions
  • Drug: Brimonidine Tartrate Ophthalmic 0.025% — Lumify is an approved eye drop to minimize ocular hyperemia.
Study Locations (1 sites)
Vision Source, Kansas City, Missouri 64111 United States
Eligibility Criteria
Inclusion Criteria: * 1\. Adult patients 18-65 years old diagnosed with open-angle glaucoma or ocular hypertension. 2\. Currently on netarsudil 0.02%/latanoprost 0.005% monotherapy for a minimum of 2-6 weeks. 3\. Able to move from current topical glaucoma treatment to netarsudil 0.02%/latanoprost 0.005% for a minimum of 4 weeks or longer based on FDA recommended washout per drug classification prior to Visit 3. 4\. Experience conjunctival redness as graded on the Efron scale of at least grade 2 after minimum of 4 weeks on netarsudil 0.02%/latanoprost 0.005% mono-therapy or longer based on recommended washout per drug classification 4. Have a best corrected Visual Acuity by Snellen chart of 20/30 or better in study eye. 5\. Are willing and able to self-administer or have an able person available to assist with administration of study drug. Willing and able to comply with study procedures and attend follow-up visits. Exclusion Criteria: 1. Allergy or hypersensitivity to brimonidine or other components of brimonidine tartrate 0.025% or netarsudil 0.02%/latanoprost 0.005%. 2. Use of any other topical ocular medications. 3. Active ocular infection, inflammation unrelated to glaucoma therapy, uveitis, iritis or congenital aphakia. 4. Have pterygium/pinguecula, chemosis, episcleritis, scleritis (or any condition that may affect hyperemia grading) in the opinion of the investigator 5. Have moderate or severe dry eyes. 6. Pregnant, plan to become pregnant or breastfeeding. 7. Concurrent or past use in the last 90 days of vasoconstrictive ocular drops other than brimondine 0.025% 8. Have undergone previous incision IOP lowering surgeries. 9. Have undergone previous laser surgery for glaucoma (selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT)), or microinvasive glaucoma surgery (MIGS) with 6 months of screening. 10. Have had intraocular or per-ocular surgery within the past 3 months. 11. Advanced glaucoma or c/d ratio greater than 0.8. Are non-responsive to topical treatment with netarsudil 0.02%/latanoprost 0.005%. 12. In the judgement of the investigator, have previous or currently active clinically significant systemic or ocular disease in either eye that could affect study outcomes.
Conditions Acute Necrotizing Pancreatitis, Portal H...
Phase NA
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). The study aims to study the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Splenectomy — Open Debridement combined with distal pancreatectomy and total splenectomy
  • Procedure: Control — Open Debridement alone

Primary Outcomes

  • Length of hospital stay after debridement (From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years))
  • Degree of pancreatic sinistral portal hypertension (From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-30
Completion: 2028-02-29
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang University
Contact Information
Study Contact:
Yun Zhang
086-18058715288
bigzyun1977@zju.edu.cn
Jian Zhang
086-18758197996
johnzhang@zju.edu.cn
Ting-Bo Liang
086-571-87236688
liangtingbo@zju.edu.cn
First Affiliated Hospital, Zhejiang University School of Medicine
Interventions
  • Procedure: Splenectomy — Open Debridement combined with distal pancreatectomy and total splenectomy
  • Procedure: Control — Open Debridement alone
Study Locations (1 sites)
First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 China
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 75 years. 2. Acute necrotic pancreatitis complicated by pancreatic sinistral portal hypertension. 3. Patients undergoing open debridement for infected pancreatic necrosis Exclusion Criteria: 1. Patients with pre-existing heart, lung, liver, kidney, or other organ failure prior to acute pancreatitis (AP). 2. Patients with pre-existing conditions such as cirrhosis that may lead to portal hypertension prior to AP. 3. Patients with pre-existing hematological diseases prior to AP. 4. Patients undergoing laparoscopic or nephroscopic debridement.
Conditions Uncontrolled Hypertension
Phase PHASE2
Enrollment 252
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: SAL0140 — SAL0140 Tablets
  • Drug: SAL0140 — SAL0140 Tablets
  • Drug: SAL0140 — SAL0140 Tablets
  • Drug: Placebo — Placebo

Primary Outcomes

  • The baseline change in mean seated systolic blood pressure (msSBP) (at week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-09
Completion: 2027-07-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Contact Information
Study Contact:
Jun Cai, professor
13810615602
caijun7879@126.com
Jun Cai, professor
13810615602
caijun7879@126.com
Beijing Anzhen Hospital Capital Medical University
Interventions
  • Drug: SAL0140 — SAL0140 Tablets
  • Drug: SAL0140 — SAL0140 Tablets
  • Drug: SAL0140 — SAL0140 Tablets
  • Drug: Placebo — Placebo
Study Locations (1 sites)
Beijing Anzhen Hospital Capital Medical University, Beijing, Beijing Municipality 100029 China
Eligibility Criteria
Inclusion Criteria: 1. Patients 18-75 years old, male or female. 2. Mean seated systolic blood pressure (msSBP) at screening was ≥140 mmHg and \<180 mmHg. 3. Meet either item A or B at screening: A. Uncontrolled hypertension (uHTN); B. Resistant hypertension (rHTN). 4. Mean seated systolic blood pressure (msSBP) prior to randomization was ≥140 mmHg and \<180 mmHg. 5. Voluntarily participate in this study and sign the informed consent form. 6. Agree to comply with contraception and fertility restrictions of this study. Exclusion Criteria: 1. Severe hypertension (msSBP ≥ 180 mmHg and/or msDBP ≥ 110 mmHg); malignant hypertension, hypertensive emergency, hypertensive crisis, hypertensive encephalopathy, etc. 2. Compliance with study drug during the run-in period was less than 80% or greater than 120%. 3. Hypertension complicated with the following conditions: acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, stroke. 4. Positive results for any of human immunodeficiency virus antibody (HIV), hepatitis C virus antibody (HCV), treponema pallidum antibody (TP); or positive hepatitis B surface antigen (HBsAg) with HBVDNA ≥ 1000 IU/mL. 5. Patients with active malignant tumors. 6. Patients receiving hemodialysis or adhering to strict salt restriction therapy. 7. History of adrenal insufficiency. 8. History of solid organ or bone marrow transplantation. 9. Gastrointestinal diseases or post-gastrointestinal surgery. 10. Known or suspected hypersensitivity to aldosterone synthase inhibitors; known or suspected contraindications or hypersensitivity to background medications. 11. History of drug abuse or alcohol abuse. 12. Blood donation or significant blood loss.
Conditions Preeclampsia, Immunologic Disease, Antip...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS. To construct reference intervals of placental angiogenesis markers specific to women affected by primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1/PlGF ratio during the trimesters of gestation (I TM, II TM and III TM). For this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood) — Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
  • Other: Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood) — Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.

Primary Outcomes

  • To construct reference ranges of placental angiogenesis markers specific to women with primary APS in pregnancy (six month after the end of the study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-12-06
Completion: 2026-06-06
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS San Raffaele
Contact Information
Study Contact:
Patrizia Rovere Querini
+390226436095
rovere.patrizia@hsr.it
Valentina Canti
+390226436095
canti.valentina@hsr.it
Patrizia Rovere Querini, PhD,MD
+390226433065
rovere.patrizia@hsr.it
San Raffaele Hospital
Interventions
  • Other: Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood) — Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
  • Other: Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood) — Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
Study Locations (1 sites)
San Raffaele Hospital, Milan, Italy
Eligibility Criteria
Inclusion Criteria: * Group 1 1. Pregnant patients between the ages of 18 and 45 years. 2. Diagnosis of primary APS, according to international classification criteria. * Group 2 1. Pregnant patients between the ages of 18 and 45 years. 2. Patients with at least one previous full-term pregnancy. 3. No diagnosis of APS, according to international classification criteria. Exclusion Criteria: * Group 1 1. PMA pregnancies. 2. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology 3. Previous thrombotic event 4. Chronic renal failure not related to AD 5. Previous history of oncology * Group 2 1. Pregnancy by PMA. 2. Previous history of polyabortion and/or late pregnancy complications. 3. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology 4. Previous thrombotic event 5. Previous history of oncology
Conditions Preeclampsia Severe, Toxemia Of Pregnanc...
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin started in the first trimester reduces the risk of preeclampsia in high-risk women. Low molecular weight heparin (LMWH) has shown potential benefits in addition to aspirin for preventing preeclampsia through its anticoagulant, anti-inflammatory, and endothelial protective effects. However, current evidence is limited and conflicting regarding the added value of LMWH to aspirin. This randomized controlled trial aims to evaluate the efficacy of combined aspirin and LMWH, compared to aspirin alone, for reducing the incidence of preeclampsia in high-risk gravidas.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Aspirin — Aspirin 160 mg orally once daily before bedtime. Duration: From enrollment (\<16 weeks gestation) until 36 weeks gestation.
  • Drug: Tinzaparin — Weight-adjusted tinzaparin administered subcutaneously once daily in the morning: 4,500 Anti-Xa IU/day for weight ≤60 kg, 6,000 Anti-Xa IU/day for weight 60-90 kg, and 8,000 Anti-Xa IU/day for weight \>90 kg. Duration: From enrollment (\<16 weeks gestation) until 36 weeks gestation.

Primary Outcomes

  • Incidence of Preeclampsia (From enrollment until delivery (up to 40 weeks gestation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-01-18
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alexandra Hospital, Athens, Greece
Principal Investigators:
  • Georgios Daskalakis, PhD (STUDY_CHAIR) - First Department of Obstetrics and Gynecology, Alexandra Hospital
Contact Information
Study Contact:
Dimitrios Baroutis, MD, MSc, PhD(c)
+306978275745
dbaroutis@gmail.com
Dimitrios Baroutis, MD, MSc, PhD(c)
+30 6978275745
dbaroutis@gmail.com
First Department of Obstetrics and Gynecology, Alexandra Hospital
Georgios Daskalakis, MD, PhD
+30 6945235757
gdaskalakis@yahoo.com
First Department of Obstetrics and Gynecology, Alexandra Hospital
Interventions
  • Drug: Aspirin — Aspirin 160 mg orally once daily before bedtime. Duration: From enrollment (\<16 weeks gestation) until 36 weeks gestation.
  • Drug: Tinzaparin — Weight-adjusted tinzaparin administered subcutaneously once daily in the morning: 4,500 Anti-Xa IU/day for weight ≤60 kg, 6,000 Anti-Xa IU/day for weight 60-90 kg, and 8,000 Anti-Xa IU/day for weight \>90 kg. Duration: From enrollment (\<16 weeks gestation) until 36 weeks gestation.
Study Locations (1 sites)
First Department of Obstetrics and Gynecology, Alexandra Hospital, Athens, Attica 11528 Greece
Eligibility Criteria
Inclusion Criteria: * Singleton pregnancy * High risk for preeclampsia (risk \>1:150) based on FMF screening algorithm combining first-trimester ultrasound, biochemical markers, and medical history * Gestational age \<16 weeks at enrollment * Maternal age ≥18 years * Willing and able to provide written informed consent * Adequate ability for follow-up (direct telephone communication, accessible residence) Exclusion Criteria: * Multiple pregnancy * Current permanent aspirin use for other medical indications * Serious congenital fetal abnormality detected on ultrasound * Contraindication to aspirin or low molecular weight heparin including: known hypersensitivity, active peptic ulcer disease, bleeding disorders or coagulopathy, severe thrombocytopenia (platelet count \<100,000/μL), active or recent significant bleeding, history of heparin-induced thrombocytopenia * Pre-existing severe renal failure (creatinine clearance \<30 mL/min) * Unable to provide informed consent * Low probability of adequate follow-up (residence in remote areas without telephone access, accommodation in temporary structures)
Conditions Hypertension, High Blood Pressure
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB# 100221MP2A), the purpose of which is to improve cardiometabolic health in two uniquely comparable cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves separate but related projects that aim to improve cardiometabolic health outcomes through better risk factor control for three chronic conditions that are of tremendous public health importance, (hypertension (HTN), heart failure, and coronary heart disease), all of which contribute significantly to premature death in Detroit and Cleveland. The present study is the prospective observational cohort component of ACHIEVE P1- EPI (Project 1) of the ACHIEVE GREATER Center and serves to characterize the population of patients with blood pressure (BP) levels above normal attending The Wayne Health Mobile Health Unit (MHU) events to better understand key factors (e.g., social determinants of health) that convey information about baseline BP levels and related clinical outcomes (e.g., follow-up clinic visits, BP control, and cardiovascular events).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Text Message Reminder — Randomized selection of recruited participants that will receive text messages reminding them to take their blood pressure.

Primary Outcomes

  • Measure Blood Pressure Protocol Fidelity (12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-11
Completion: 2028-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wayne State University
Principal Investigators:
  • Steven J Korzeniewski, PhD (PRINCIPAL_INVESTIGATOR) - Wayne State University
Contact Information
Study Contact:
Phillip Levy, MD, MPH
313-577-1214
plevy@med.wayne.edu
Katee Dawood, MBA
313-577-1232
kdawood@wayne.edu
Laura Schulz
lschulz@med.wayne.edu
Wayne Health Mobile Units
Interventions
  • Behavioral: Text Message Reminder — Randomized selection of recruited participants that will receive text messages reminding them to take their blood pressure.
Study Locations (1 sites)
Wayne Health Mobile Units, Detroit, Michigan 48201 United States
Eligibility Criteria
Inclusion Criteria: * Mobile Health Unit Patients with blood pressure above normal (≥120 systolic and/or ≥80 mmHg) * Has a phone with the ability to receive text messages * 18+ years old * Consent to allow prospective follow-up including through EHR review Exclusion Criteria: * Non-mobile health unit patients * MHU patients with systolic BP \< 120 mmHg AND diastolic BP \< 80 mmHg * Pregnant Women * Children less than 18 years old * Individuals viewed by the investigative team as unable to understand and sign the informed consent form * Currently enrolled in another on-going interventional trial initiated on the mobile health unit